Lv1
30 积分 2021-09-09 加入
Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases
4天前
已完结
YTHDF3 Drives Tumor Growth and Metastasis by Recruiting eIF4B to Promote Notch2 Translation in Breast Cancer
1个月前
已完结
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
5个月前
已完结
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
6个月前
已完结
A translational framework to DELIVER nanomedicines to the clinic
6个月前
已完结
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
7个月前
已完结
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts
10个月前
已完结
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC
10个月前
已完结
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1
1年前
已完结
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR
1年前
已关闭
皖公网安备34019202002308
